A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.

Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma Not Amenable to Resection or Transplant.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Rose bengal sodium (Primary)
  • Indications Liver cancer; Liver metastases
  • Focus Adverse reactions
  • Sponsors Provectus Biopharmaceuticals
  • Most Recent Events

    • 22 Dec 2016 According to Provectus Biopharmaceuticals media release, abstracts having the data of this study accepted at international oncology conferences and will be presented at Clinical Interventional Oncology (CIO) and 26th Conference of the Asian Pacific Association for the Study of the Liver (APASL) in Feb 2017
    • 29 Oct 2016 Planned number of patients changed from 42 to 66.
    • 29 Oct 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top